AbbVie Inc. (ABBV)
NYSE • Healthcare
November 17, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, AbbVie Inc. keeps $24 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 3
in 77 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
AbbVie’s adjusted EPS topped expectations while revenue came in line in the third fiscal quarter of 2026, based on preliminary results reported October 30, 2026. Adjusted EPS was $3.82 versus a $3.73 estimate (+2.4%, topped), as revenue rose 10.3% to roughly $17.4 billion (up from about $15.8 billion a year ago) and revenue of $17.404 billion was in line with a $17.316 billion estimate (+0.5%). Profitability remained high, with gross margin at about 85% and operating margin near 37%, as gross profit came in around $14.8 billion and operating income was roughly $6.5 billion. Net income was about $4.2 billion, up 2169.9% from roughly $186.0 million a year ago. Consensus for the next period calls for EPS of $3.90 on revenue of $18.284 billion.
About AbbVie Inc.
AbbVie Inc. (NYSE: ABBV) is a healthcare company that discovers, develops, manufactures, and commercializes advanced medicines across immunology, oncology, neuroscience, eye care, and other therapeutic areas around the world. In Drug Manufacturers - General, AbbVie generated $61.2 billion of revenue in FY2025.
Today's Snapshot
The day ended with ABBV 0.6% lower at 292.78, in line with a weaker sector. Trading was lighter than usual, with volume about half of its usual level.
Trading Volume
Below 10d avg (5.0M)
2.4M
vs S&P 500 Today
Outperforming Market
+0.75%
Updated: November 17, 2026 at 21:12 UTC
ABBV Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$248.49 - $292.85Buy
- RSI (14)58.70Neutral
- Stochastic %K (14, 3, 3)59.76Neutral
- MACD Level (12, 26)4.79Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.